Bravecto® Spot-On Solution for Dogs
Bravecto Spot-On for Dogs is indicated for the treatment of fleas and ticks. Based on the isoxazoline active ingredient, fluralaner, a duration of efficacy for both fleas and ticks has been demonstrated for up to 12 weeks* following topical administration.
Bravecto contributes towards the control of the environmental flea populations due to the rapid onset of action and long lasting efficacy against adult fleas on the animal and the absence of viable egg production.
Information on ordering Bravecto is available after login.
Presentation
Bravecto Spot-On Solution is a clear colourless to yellow spot-on formulation.
Active ingredients
Each ml contains 280 mg fluralaner.
Target species
Dogs
Indications for use:
This veterinary medicinal product is a systemic insecticide and acaricide that provides:
- Immediate and persistent flea (Ctenocephalides felis and Ctenocephalides canis) killing activity for 12 weeks.
- Immediate and persistent tick (Ixodes ricinus, Rhipicephalus sanguineus and Dermacentor reticulatus) killing activity for 12 weeks.
- Used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
- For the treatment of demodicosis caused by Demodex canis.
- For the treatment of sarcoptic mange (Sarcoptes scabei var. canis) infestation.
Bravecto Spot-on for dogs can be used from 8 weeks of age and 2 kg in bodyweight.
Packaging
Each box contains 1 pipette made of laminated aluminium/polyproplene foil closed with an HDPE cap and packed in laminated aluminium foil sachet.
Legal Category
POM-V
Further information is available from the SPC, datasheet or package leaflet.
Advice should be sought from the medicine prescriber.
Prescription decisions are for the person issuing the prescription alone.
Use Medicines Responsibly.
Date of preparation: January 2025
References
*Bravecto Spot-on has 12-week duration of efficacy against flea and tick species indicated in the SPC. Bravecto Chewable Tablets include an 8-week immediate and persistent killing activity against Rhipicephalus sanguineus. For further information refer to the relevant SPC.